Brief: GRI Bio Announces FDA Clearance Of IND For Lead Program GRI-0621 For The Treatment Of Idiopathic Pulmonary Fibrosis

GRI Bio

27/11/2023 14:40

Nov 27 (Reuters) - GRI Bio Inc  GRI.O :
    * GRI BIO (NASDAQ: GRI) ANNOUNCES FDA CLEARANCE OF IND FOR
LEAD
PROGRAM GRI-0621, A TYPE 1 INVARIANT NKT (“INKT”) ANTAGONIST FOR
THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (“IPF”)
    * GRI BIO INC - INITIATION OF PHASE 2A BIOMARKER STUDY ON
TRACK TO
START BEFORE YEAR END

Source text for Eikon:  ID:nGNXqXLMY 
Further company coverage:  GRI.O 

 ((Reuters.Briefs@thomsonreuters.com;))